2023-04-27-上交所-大参林医药集团股份有限公司2023年第一季度报告_12页_323kb

Dashenlin Q1 2023 Financial Summary

Key Financial Highlights

• Revenue for the quarter reached 5,946,849,853.43 yuan, showing a 27.16% increase year-over-year.
• Net profit attributable to shareholders was 496,753,444.07 yuan, up by 29.29%.
• Net profit excluding non-recurring items increased by 25.66%.
• Operating cash flows rose by 12.99%.
• Basic and diluted earnings per share rose by 7.74%, convertible to a higher return on equity increase of 12.76 percentage points.

Changes Explanations

• Key changes include a 35.57% decrease in trading financial assets due to market value fluctuations.
• Growth in operating profit and decreases in areas like taxes and employee costs are tied to business operations, including cost optimize increased R&D expense from new projects.

Shareholder Information

• Top shareholders include family members dominating with over 20% each ownership. Notably, the first three shareholders collectively hold significant stakes with some holdings pledged or structured.

Strategic Activities

• Significant investment activities occurred, with seven transactions, including one acquisition for 75 stores already closed and five new deals for a total of 371 stores planned or pending. These efforts enhance the company's market position.

Overall Performance

• Dashenlin maintained strong growth in revenue and profits, supported by effective operations and strategic expansion, but faced minor declines in non-core areas like cash flow investments due to stricter financial management.